BPH Drug Pipeline: NO, Beta-3 & MIS — PatSnap Eureka
Benign Prostatic Hyperplasia Drug Pipeline: Nitric Oxide, Beta-3 Agonist & Minimally Invasive Approaches
BPH affects more than 75–80% of men over 50, driving a rapidly diversifying patent landscape across NO/cGMP modulators, beta-3 adrenergic agonism, and intraprostatic drug delivery. Explore the mechanistic clusters, assignee activity, and emerging translational signals shaping next-generation BPH pharmacotherapy.
BPH Molecular Target Patent Density
Relative patent filing intensity across key BPH targets in the retrieved dataset.
Understanding BPH: From Pathology to Molecular Targets
Benign prostatic hyperplasia is a noncancerous proliferation of glandular epithelial tissue, smooth muscle, and connective tissue within the prostate transition zone, causing progressive bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS) encompassing voiding symptoms—hesitancy, intermittent stream, straining—and storage symptoms including urgency, nocturia, and overactive bladder. According to WHO global health data, BPH represents one of the most common urological conditions in aging males worldwide.
The therapeutic landscape has evolved substantially from classical hormonal and adrenergic modulation toward mechanistically diverse approaches. The PDE5/cGMP/nitric oxide axis is the most densely covered target cluster in patent filings, with smooth muscle relaxation in the prostatic stroma and urethra via cGMP accumulation as the central mechanism. Upstream of PDE5, soluble guanylate cyclase (sGC) represents a further differentiation point, particularly in patients with low NO bioavailability. Explore the full patent landscape with PatSnap Eureka's life sciences intelligence platform.
The beta-3 adrenergic receptor (ADRB3) has emerged as a clinically differentiated target for the storage symptom component of LUTS/BPH—specifically detrusor overactivity and OAB—which alpha-1 blockers and 5-alpha reductase inhibitors do not adequately resolve. Vibegron (Urovant Sciences) is the representative compound, studied at 75 mg/day in men with BPH. The NIH has documented the substantial comorbidity burden of BPH and OAB in aging male populations.
Minimally invasive intraprostatic drug delivery represents the most actively filed emerging modality in the dataset, with Resurge Therapeutics' sustained-release cytostatic formulations and Nymox Corporation's fexapotide triflutate peptide platform both carrying active or pending patent status as of 2023–2026. Learn more about PatSnap's life sciences IP analytics for drug pipeline monitoring.
Six Mechanistic Clusters Shaping the BPH Pipeline
From approved PDE5 inhibitors to emerging intraprostatic delivery platforms, the BPH patent landscape spans six mechanistically distinct therapeutic approaches with varied development stages.
Nitric Oxide / sGC / PDE5 Pathway Modulators
The therapeutic rationale centers on increasing smooth muscle relaxation in the prostatic stroma and urethra via cGMP accumulation—either by blocking PDE5-mediated cGMP degradation or by directly stimulating upstream sGC. Dong-A Pharmaceutical's pyrazolopyrimidinone compound claims pharmacokinetic advantages over comparator PDE5 inhibitors (shorter Tmax, longer half-life). Bayer Schering's 2009 patent covers sGC stimulators and activators combined with PDE5 inhibitors, amplifying cGMP signaling at two pathway points.
Approved (tadalafil) → Preclinical (novel agents)Beta-3 Adrenergic Receptor Agonism (Vibegron)
Urovant Sciences' 2021 filing (Indonesia) describes oral vibegron at 75 mg/day for OAB symptoms specifically in men with BPH. ADRB3 agonism on detrusor smooth muscle produces bladder relaxation without blocking bladder contractility at voiding—addressing storage symptoms that alpha-1 blockers and 5-alpha reductase inhibitors do not adequately resolve. This modality is positioned as a potential add-on to standard BPH therapy in men with persistent storage symptoms.
Clinical Signal — BPH+OAB Indication ExpansionMinimally Invasive Intraprostatic Drug Delivery
Resurge Therapeutics filed two active US patents (2023, 2026 pending) describing sustained-release cytostatic/cytotoxic drug formulations using an applicator with a specific KIR rheological value of 40–400 centipoise per unit area for controlled drug release to prostatic tissue. Nymox Corporation's fexapotide triflutate (NX-1207) involves intraprostatic injection of a proapoptotic peptide (sequence: Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu), with clinical data showing IPSS obstructive symptom improvements of 30–150%.
Late Clinical (Nymox) → IND-Enabling (Resurge)Androgen / 5-Alpha Reductase Modulators & SARMs
Classical 5-alpha reductase inhibitors (finasteride, dutasteride) combined with alpha-1 blockers remain approved standards. University of Tennessee Research Foundation and GTX Inc. (now Oncternal Therapeutics) proposed SARMs capable of simultaneously inhibiting 5-alpha reductase type 1 and 2 and modulating AR signaling. However, multiple SARM filings for BPH are now inactive, suggesting this modality has not translated commercially for the BPH indication.
Approved (combo) · SARM IP largely lapsedEGFR Pathway Inhibition
Boehringer Ingelheim filed at least four patents (US, CA, JP, 2003–2011) proposing EGFR tyrosine kinase inhibitors for BPH treatment, based on EGF receptor-driven stromal and epithelial cell proliferation. These patents indicate combination with alpha-1 blockers, 5-alpha reductase inhibitors, and muscarinic antagonists. All retrieved Boehringer Ingelheim EGFR-BPH patents are now inactive, which may indicate strategic abandonment of this approach.
Patent Only — No Clinical Translation SignalPulsed Electromagnetic Field Therapy (PEMF)
Sapienza University of Rome published a 2020 prospective pilot trial in 27 naive BPH patients using a perineal PEMF device (1–50 Hz), reporting reductions in prostate volume (transrectal ultrasound), IPSS, and IIEF-15 scores. The rationale is that chronic low-grade inflammation drives BPH pathogenesis. This represents the most explicit clinical evidence retrieved, though sample size is small and the study is described as a pilot.
Pilot Clinical Evidence — Small Sample (n=27)BPH Pipeline: Development Stage & Assignee Activity
Patent filing timelines, development stage distribution, and key assignee activity derived from the retrieved patent and literature dataset.
BPH Pipeline Modality Development Stage Distribution
Development stage mapping across BPH therapeutic modalities from approved combinations through patent-only stages, based on retrieved patent records via PatSnap Eureka.
Key BPH Assignee Patent Filing Activity Timeline
Temporal distribution of patent filing activity across major BPH assignees, showing Bayer's earlier IP prosecution phase (2007–2009) versus Nymox and Resurge's more recent activity (2018–2026).
Key Commercial Drivers in the BPH Patent Dataset
Patent activity predominates in this dataset, with commercial drivers spanning large pharma, biotech, and individual inventors across multiple geographies and mechanistic clusters.
| Assignee | Modality / Target | Filing Period | Key Jurisdictions | IP Status Signal |
|---|---|---|---|---|
| Bayer Healthcare / Bayer Schering Pharma | PDE5/PDE4 inhibitor combinations; sGC stimulators/activators | 2007–2009 | CA, TW, TN, JP, MX | Earlier IP prosecution phase |
| Nymox Corporation | Fexapotide triflutate (NX-1207) intraprostatic peptide | 2018–2025 | EP, WO, AU, JP, ID | Most temporally recent cluster |
| Resurge Therapeutics, Inc. | Sustained-release intraprostatic cytostatic delivery | 2023–2026 | US (active/pending) | Active commercial development |
| Urovant Sciences GmbH | Vibegron for BPH+OAB (beta-3 agonist) | 2021 | ID (active) | BPH indication expansion |
| Dong-A Pharmaceutical Co., Ltd. | Pyrazolopyrimidinone PDE5 inhibitor for BPH | 2011 | BR, RU, JP (active) | Ongoing JP prosecution |
Monitor BPH IP Activity with PatSnap Analytics
Track new filings, assignee changes, and prosecution status across the full BPH patent landscape.
Meaningful Clinical Evidence in the BPH Dataset
Retrieved results contain several meaningful clinical and translational signals spanning controlled trials, clinical dosing data, and pilot studies.
Nymox Fexapotide Triflutate (NX-1207): Double-Blind RCT Data
Multiple Nymox filings reference an explicitly described double-blind, placebo-controlled, urologist-administered clinical trial. NX-1207-treated patients showed IPSS obstructive symptom improvements of 30–150% versus placebo-treated controls. Surgery avoidance is described as a clinical endpoint across AU and JP filings. A 2025 pending JP filing identifies patients with LUTS but without BPH as a target population, signaling indication expansion.
Vibegron in BPH Men: Clinical Dosing Signal (75 mg/day)
The Urovant Sciences filing specifies an oral dose range of 60–90 mg (exemplified at 75 mg/day) in men with BPH, indicating this is a dosing regimen derived from or consistent with clinical data. This represents a clinically differentiated positioning signal for the beta-3 agonist modality's most direct BPH application in the dataset, with the specific BPH+OAB indication suggesting an ongoing effort to extend the approved OAB label into the male LUTS/BPH population.
PEMF Pilot Study: Prostate Volume & IPSS Reductions (n=27)
The Sapienza University of Rome academic paper reports a 27-patient prospective interventional trial using a perineal PEMF device (1–50 Hz), with measurable changes in prostate volume (transrectal ultrasound), IPSS, and IIEF-15 scores. This is the most explicit clinical evidence retrieved, though sample size is small and the study is described as a pilot. The rationale is that chronic low-grade inflammation drives BPH pathogenesis.
Dong-A PDE5 Inhibitor: Pharmacokinetic Differentiation Claim
Dong-A Pharmaceutical's filings for the pyrazolopyrimidinone PDE5 inhibitor claim pharmacokinetic advantages over other PDE5 inhibitors—specifically shorter Tmax and longer half-life—language typically derived from clinical pharmacology studies. Evidence derives from both patent families in Brazil (inactive) and Japan (active), with the Japanese filing indicating ongoing prosecution.
Seven Combination Approaches Signaled in Retrieved Results
The BPH patent dataset reveals a clear trend toward multi-target combination strategies addressing both voiding obstruction and storage symptoms simultaneously.
PDE5 Inhibitor + sGC Stimulator
Bayer Schering's 2009 patent explicitly covers the combination of sGC stimulators/activators with PDE5 inhibitors, amplifying cGMP signaling at two points in the pathway. This is a potential strategy for patients with suboptimal PDE5 monotherapy response, particularly in cases with low NO bioavailability where upstream sGC stimulation may provide additive benefit.
Two-point cGMP amplificationPDE5 + PDE4 Dual Inhibition
Bayer Healthcare patents (2007–2009) covering PDE5+PDE4 inhibitor combinations for BPH/LUTS/BOO suggest that targeting the cAMP (PDE4) and cGMP (PDE5) pathways simultaneously may address both smooth muscle tone and inflammatory components of BPH-related LUTS.
cAMP + cGMP dual targetingAlpha-1 Blocker + Muscarinic Antagonist
Multiple filings—Astellas (tamsulosin+solifenacin), Aspen Global/Novartis (alpha antagonist+muscarinic antagonist)—address dual voiding and storage symptom control. This combination addresses the common clinical reality of mixed LUTS in men with BPH. The EMA has reviewed combination LUTS products reflecting this clinical need.
Voiding + storage symptom controlBeta-3 Agonist as BPH+OAB Add-On
Urovant's vibegron filing signals that beta-3 agonism may be positioned as an add-on to standard BPH therapy (alpha-1 blocker ± 5-alpha reductase inhibitor) in men with persistent storage symptoms. The Dainippon Sumitomo quinazolinone patent also references beta-3 agonists as potential combination partners alongside PDE5 inhibitors and alpha-1 blockers for LUTS treatment.
OAB comorbidity managementIP Strategy Signals for BPH Drug Developers
Key strategic signals derived from the patent dataset for R&D teams, IP strategists, and business development professionals monitoring the BPH pipeline. Access the full PatSnap IP analytics platform for deeper landscape analysis.
NO/cGMP: Dense IP but sGC Differentiation Opportunity
The NO/cGMP axis remains the most patent-dense mechanistic space in this dataset, with sGC stimulation upstream of PDE5 representing an underexploited differentiation opportunity. Drug developers pursuing this pathway may face IP density from Bayer but have design space in novel sGC stimulator chemotypes distinct from riociguat-class compounds.
Vibegron BPH+OAB: Large Label Expansion Opportunity
Beta-3 agonism (vibegron) in BPH men represents a clinically differentiated positioning signal. The specific BPH+OAB indication in Urovant's active Indonesian filing suggests an ongoing effort to extend the approved OAB indication into the male LUTS/BPH population—a potentially large label expansion opportunity given the high comorbidity prevalence.
BPH Drug Pipeline — key questions answered
The NO/cGMP axis remains the most patent-dense mechanistic space in the BPH dataset, with sGC stimulation upstream of PDE5 representing an underexploited differentiation opportunity. Drug developers pursuing this pathway may face IP density from Bayer but have design space in novel sGC stimulator chemotypes distinct from riociguat-class compounds.
Beta-3 agonism (vibegron) addresses the storage symptom component of LUTS/BPH—specifically detrusor overactivity and OAB—which alpha-1 blockers and 5-alpha reductase inhibitors do not adequately resolve. The mechanism involves ADRB3 agonism on detrusor smooth muscle, producing bladder relaxation without blocking bladder contractility at voiding.
Multiple Nymox filings reference an explicitly described double-blind, placebo-controlled, urologist-administered clinical trial. Retrieved data reports: antibiotic pretreatment + NX-1207 versus PBS placebo; 12-month Qmax improvement in placebo arm comparable to conventional oral BPH drugs; treatment arm showed additional benefit. The IPSS-based MOVS endpoint improvement of 30–150% versus placebo-treated controls is reported.
SARM-based IP for BPH is largely lapsed, with multiple inactive filings from University of Tennessee and GTX Inc., suggesting this modality has not translated commercially for the BPH indication specifically. The window for building IP position around SARMs in BPH may have passed without clinical validation.
Resurge Therapeutics filed two active US patents describing sustained-release cytostatic/cytotoxic drug formulations for local intraprostatic delivery, using an applicator-based delivery system with a specific KIR (rheological) value of 40–400 centipoise per unit area for controlled drug release to prostatic tissue. These represent a minimally invasive approach aiming to avoid systemic pharmacological exposure while achieving local tissue cytostasis.
Retrieved results signal several combination strategies: PDE5 inhibitor combined with sGC stimulator to amplify cGMP signaling at two pathway points; PDE5 and PDE4 dual inhibition targeting both cAMP and cGMP pathways simultaneously; alpha-1 blocker combined with muscarinic antagonist for mixed LUTS; and beta-3 agonist as add-on to standard BPH therapy in men with persistent storage symptoms.
Still have questions about the BPH drug pipeline? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About BPH →Accelerate Your BPH Drug Pipeline Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track patent landscapes, identify white space, and monitor competitive assignee activity in urology and beyond.
References
- Agent for the Prevention and Treatment of Prostatic Hyperplasia Comprising Pyrazolopyrimidinone Compound — Dong-A Pharmaceutical Co., Ltd., 2011, BR [Patent]
- sGC Stimulators, sGC Activators and Combinations for the Treatment of Urological Disorders — Bayer Schering Pharma AG, 2009, MX [Patent]
- PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders — Bayer Healthcare AG, 2007, CA [Patent]
- PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders — Bayer Healthcare AG, 2009, TN [Patent]
- Vibegron for Treatment of Overactive Bladder Disease Symptoms — Urovant Sciences GmbH, 2021, ID [Patent]
- Treating Benign Prostatic Hyperplasia — Resurge Therapeutics, Inc., 2023, US [Patent]
- Apparatus for Treating Benign Prostatic Hyperplasia — Resurge Therapeutics, Inc., 2026, US [Patent]
- Method of Improving Lower Urinary Tract Symptoms — Nymox Corporation, 2025, JP [Patent]
- Method of Ameliorating or Preventing the Worsening or the Progression of Symptoms of BPH — Nymox Corporation, 2019, EP [Patent]
- How to Improve Lower Urinary Tract Symptoms — Nymox Corporation, 2022, JP [Patent]
- Treatment of Benign Prostatic Hyperplasia Using Antibiotics — Nymox Corporation, 2021, JP [Patent]
- Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in BPH — Sapienza University of Rome, 2020 [Literature]
- World Health Organization — Global Urological Health Data
- National Institutes of Health — BPH and OAB Comorbidity Research
- European Medicines Agency — LUTS Combination Product Reviews
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.